Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasm Metastasis 1Metastatic Solid Tumors 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Carcinoma in Situ 1Carcinoma 1

Interventions

tislelizumab 1bintrafusp alfa protein, human 1avelumab 1Tomography, X-Ray Computed 1Nivolumab 1Ipilimumab 1Injections 1Infusions, Intravenous 1Gemcitabine 1Electrocardiography 1Echocardiography 1DOXO-EMCH 1Cetuximab 1(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Metastatic Solid Tumors × Electrocardiography × Clear all
NCT03388632 2025-12-18

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
31 enrolled 20 charts
Other solid neoplasm

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡